Semnur Pharmaceuticals, Inc. (SMNRW)
US Markets
$0.14
+95.95%
Closing price as of 2026-08-27 · Source: TEK2day Finance
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (152.6M) | (6.2M) | (4.6M) | (4.2M) |
| Net Income | (152.6M) | (6.2M) | (4.6M) | (4.3M) |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (3.8M) | (3.3M) | (4.7M) | (160.4M) |
| Net Income | (3.8M) | (3.3M) | (4.7M) | (160.4M) |